Hicklin headshot

Dan Hicklin, Ph.D.

Executive Partner

Executive Partners

Cambridge Office

Dr. Dan Hicklin is an accomplished cancer researcher and biopharmaceutical executive with nearly three decades of oncology drug development experience. Dan joined MPM following his successful role as President and CSO and member of the board of MPM portfolio company CoStim Pharmaceuticals (acquired by Novartis). He is currently founder, President and CEO of Potenza Therapeutics and founder and President of Trieza Therapeutics, two MPM immuno-oncology portfolio companies. Dan is also a board member of MPM portfolio companies Maverick Therapeutics, Tizona Therapeutics and Werewolf Therapeutics, and a member of the scientific advisory board of Oncorus.

Over the course of his career, Dan has developed strong scientific and leadership skills across all phases of small molecule and biologics drug development. Prior to CoStim, Dan held several positions at Merck Research Laboratories (formerly the Schering-Plough Research Institute prior to its acquisition by Merck), including leading their Biologics Strategy for Oncology and the Immuno-Modulation Discovery team. In these roles, he oversaw several oncology discovery and development projects including Merck’s immuno-oncology portfolio and the development of Keytruda® (pembrolizumab). Prior to joining Schering-Plough, Dan held several positions of increasing responsibility at ImClone Systems (acquired by Eli Lilly), including serving as Vice President of Experimental Therapeutics. His team at ImClone supported the development and FDA approval of the cancer treatment Erbitux® (cetuximab) and built a diversified portfolio of antibody therapeutics including Cyramza® (ramucirumab), Portrazza® (necitumumab) and other agents that were acquired by Eli Lilly.  Dan began his career as an Assistant Professor at New York Medical College.

Dan holds an M.S. and Ph.D. in Immunology from New York Medical College where he trained with Dr. Soldano Ferrone, and his B.S. from the University of Iowa.